文献速递冠心病

甘油三酯水平、阿利西尤单抗治疗与急性冠脉综合征后心血管结局

Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome.
PubMed 文献 · J Am Coll Cardiol · 2024-01-01

基于ODYSSEY OUTCOMES试验的预设与事后分析,纳入18,924例近期急性冠脉综合征且优化他汀治疗后致动脉粥样硬化脂蛋白仍升高的患者,随机接受阿利西尤单抗75-150mg或安慰剂每2周皮下注射。中位基线甘油三酯129 mg/dL,基线甘油三酯每升高10 mg/dL与调整后MACE风险增加相关(HR 1.008,95%CI 1.003-1.013,P<0.005);阿利西尤单抗较安慰剂降低MACE(HR 0.85,95%CI 0.78-0.93),但甘油三酯降低未贡献其临床获益。

要点

  • 近期ACS且优化他汀治疗后,基线甘油三酯升高与MACE风险增加独立相关。
  • 阿利西尤单抗较安慰剂显著降低MACE(HR 0.85,95%CI 0.78-0.93)。
  • 阿利西尤单抗降低甘油三酯未贡献其临床获益。

核心结论

  • 近期ACS且优化他汀治疗患者中,基线甘油三酯与心血管风险相关,但阿利西尤单抗降低甘油三酯未贡献其临床获益。

研究设计与样本

  • ODYSSEY OUTCOMES试验的预设与事后分析,纳入18,924例近期ACS且优化他汀治疗后致动脉粥样硬化脂蛋白仍升高的患者,随机接受阿利西尤单抗75-150mg或安慰剂每2周皮下注射。

主要发现

  • 中位基线甘油三酯浓度为129 mg/dL。
  • 两组中基线甘油三酯每升高10 mg/dL与调整后MACE HR 1.008(95%CI 1.003-1.013,P<0.005)相关。
  • 基线甘油三酯≥150 vs <150 mg/dL与HR 1.184(95%CI 1.080-1.297,P<0.005)相关。
  • 阿利西尤单抗较安慰剂降低LDL-C平均54.7%并降低MACE(HR 0.85,95%CI 0.78-0.93)。
  • 第4个月时,阿利西尤单抗组甘油三酯中位降低17.7 mg/dL(P<0.001),安慰剂组降低0.9 mg/dL(P=NS)。

临床怎么用

  • 近期ACS患者应关注基线甘油三酯水平以评估残余心血管风险。
  • 阿利西尤单抗用于降低MACE的获益不依赖于甘油三酯降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is unknown whether clinical benefit of proprotein convertase subtilisin/kexin type 9 inhibitors is associated with baseline or on-treatment triglyceride concentrations. OBJECTIVES: This study sought to examine relations between triglyceride levels and the effect of alirocumab vs placebo on cardiovascular outcomes using prespecified and post hoc analyses of the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial. METHODS: Patients with recent acute coronary syndrome (ACS) (n = 18,924) and elevated atherogenic lipoproteins despite optimized statin therapy were randomized to alirocumab 75 to 150 mg or matching placebo every 2 weeks subcutaneously. Major adverse cardiovascular events (MACE) were examined in relation to continuous or dichotomous triglyceride concentrations. RESULTS: Median baseline triglyceride concentration was 129 mg/dL. In both treatment groups, a 10-mg/dL higher baseline concentration was associated with an adjusted MACE HR of 1.008 (95% CI: 1.003-1.013; P < 0.005). Baseline triglycerides ≥150 vs <150 mg/dL were associated with a HR of 1.184 (95% CI: 1.080-1.297; P < 0.005). Versus placebo, alirocumab reduced low-density lipoprotein cholesterol from baseline (average, 54.7%) and reduced MACE (HR: 0.85; 95% CI: 0.78-0.93). At month 4, triglyceride levels were reduced from baseline by median 17.7 mg/dL (P < 0.001) and 0.9 mg/dL (P = NS) with alirocumab and placebo, respectively. A 10-mg/dL decline from baseline in triglycerides was associated with lower subsequent risk of MACE with placebo (HR: 0.988; 95% CI: 0.982-0.995; P < 0.005) but not with alirocumab (HR: 0.999; 95% CI: 0.987-1.010; P = 0.82). CONCLUSIONS: Among patients with recent ACS on optimized statin therapy, baseline triglycerides was associated with cardiovascular risk. However, the reduction in triglycerides with alirocumab did not contribute to its clinical benefit. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Zahger, Schwartz, Du, et al. Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome. J Am Coll Cardiol. 2024. PMID: 39232634. doi:10.1016/j.jacc.2024.06.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。